We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Blood Sample Collection Cards Used for Screening Newborns

By LabMedica International staff writers
Posted on 07 May 2009
Dried blood spot cards are used to collect and transport blood specimens from newborns, which are later analyzed by public health laboratories. More...
Newborn screening is used to detect congenital disorders, many of which are treatable only when identified during the first days of life. A significant number of these are treatable when detected, but fatal when not.

PerkinElmer, Inc. (Waltham, MA, USA) has entered into a contract with ID Biological Systems (Greenville, South Carolina, USA) to become its exclusive, worldwide distributor for dried blood spot specimen collection cards used by newborn screening programs worldwide. The agreement is intended to deliver a consistent, high-quality supply of sample collection cards designed to customer specifications.

ID Biological Systems will produce the cards using Ahlstrom grade 226 filter paper. They are manufactured according to the Clinical and Laboratory Standards Institute (CLSI) standard for blood collection on filter paper for newborn screening programs. The paper has been successfully tested to the CLSI standard by the U.S. Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) Newborn Screening Quality program and other third party testing facilities.

"To secure the supply and delivery of U.S. Food and Drug Administration (FDA; Rockville, MD, USA)-approved high quality specimen cards is a priority for PerkinElmer and our newborn screening customers," said Ann-Christine Sundell, president, genetic screening, PerkinElmer. "This agreement expands our offering with a high quality product, and provides IDB Systems with a strong and proven distribution channel for its product."

Gary Resler, health services consultant for the Newborn Screening Program in the State of Washington has been using ID Biological Systems' specimen collection cards for samples processed in his laboratory for the past nine months. "A consistent supply of high quality sample cards is an imperative in a public health laboratory processing hundreds of neonatal samples each day," said Mr. Resler. "ID Biological Systems has delivered this quality and consistency along with a tremendous level of service."

Related Links:

PerkinElmer, Inc.
ID Biological Systems
U.S. Centers for Disease Control and Prevention
U.S. Food and Drug Administration



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.